

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
22 September 2016 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the August 2016 meeting:

- ***Drug Class Reviews***
 - ***Topical Acne and Rosacea Agents***
 - ***Migraine Agents—Triptans***
 - ***Narcotic Antagonists***
- ***Innovator Drugs***
 - ***Antihemophilic Agents: antihemophilic factor VIII (recombinant) (Afstyla)***
 - ***Topical Corticosteroids: betamethasone dipropionate 0.05% spray (Sernivo)***
 - ***Anticonvulsant and Anti-Mania Agents: brivaracetam tablets and oral solution (Briviact)***
 - ***Oral Oncology Agents (Renal Cell Carcinoma): cabozantinib (Cabometyx)***
 - ***Iron Chelators: Deferiprone oral solution (Ferriprox)***
 - ***Antiretrovirals Agents: emtricitabine/ tenofovir alafenamide (Descovy)***
 - ***Topical Antineoplastic and Premalignant Lesions Agents: fluorouracil 4% cream (Tolak)***
 - ***Topical Corticosteroids: halobetasol propionate 0.05% lotion (Ultravate)***
 - ***Non-Insulin Diabetes Drugs – DPP-4 Inhibitors: linagliptin/metformin XR (Jentadueto XR)***
 - ***Miscellaneous Agents: nitisinone oral suspension (Orfadin)***

- *Miscellaneous Agents: obeticholic acid (Ocaliva)*
- *Narcotic Analgesics and Combinations: oxycodone extended-release capsules (Xtampza ER)*
- *Atypical Antipsychotics: pimavanserin (Nuplazid)*
- *Hepatitis C Virus Direct Acting Agents: sofosbuvir/velpatasvir (Epclusa)*
- *Oral Oncology Agents (Chronic Lymphocytic Leukemia): venetoclax (Venclexta)*
- *Utilization Management Issues*
 - *Prior Authorization Criteria*
 - *Analgesics and Combinations: butalbital/acetaminophen/caffeine oral liquid (Vanatol LQ)*
 - *Newer Sedative Hypnotics (SED-1s): suvorexant (Belsomra)*
 - *Growth Stimulating Agents*
 - *Topical Pain Agents: diclofenac 2% topical solution (Pennsaid)*
 - *Removal of “Brand over Generic” Prior Authorization Criteria*
 - *Antilipidemic-1s (LIP-1s): niacin ER (Niaspan)*
- *NDAA 2008 Section 703 Actions*
- *Over-the-Counter (OTC) Drugs: Second Generation Antihistamines UF Recommendation*
- *Re-Evaluation of Generic Non Formulary Agents*
 - *Second Generation Antihistamines*
 - *Osteoporosis Agents (Oral Bisphosphonates and Calcitonin)*
 - *Non-Insulin Diabetes Drugs/Biguanides*
 - *Selective Serotonin Receptor Inhibitors*
 - *Benign Prostatic Hypertrophy (BPH) Medications/5-Alpha Reductase Inhibitors*
 - *Alzheimer’s Medications:*
 - *Topical Pain Agents*
- *Panel Discussions*

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.